Risankizumab
drugOn this page
Also known as ABBV-066Bi-655066BI655066Risankizumab rzaaRisankizumab-rzaaSkyrizi
Summary
Risankizumab (CHEMBL3990029) is an approved antibody (ATC L04AC18); indicated across 12 conditions including psoriasis and immune system disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody
- ATC class: L04AC18
- Indications: 12 conditions
- Clinical trials: 74
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3990029 |
| Name | Risankizumab |
| Type | Antibody |
| Max phase | 4 |
| ATC | L04AC18 |
Also known as: ABBV-066, Bi-655066, BI655066, Risankizumab, Risankizumab rzaa, Risankizumab-rzaa, Skyrizi, RISANKIZUMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
12 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| psoriasis | 4 | MONDO:0005083 | EFO:0000676 |
| immune system disorder | 4 | MONDO:0005046 | EFO:0000540 |
| psoriatic arthritis | 4 | MONDO:0011849 | EFO:0003778 |
| Crohn disease | 3 | MONDO:0005011 | EFO:0000384 |
| ulcerative colitis | 3 | MONDO:0005101 | EFO:0000729 |
| psoriasis-related juvenile idiopathic arthritis | 3 | MONDO:0019436 | EFO:0009733 |
| ankylosing spondylitis | 2 | MONDO:0005306 | EFO:0003898 |
| hidradenitis suppurativa | 2 | MONDO:0006559 | EFO:1000710 |
| dermatitis | 2 | MONDO:0002406 | MONDO:0002406 |
| severe acute respiratory syndrome | 2 | MONDO:0005091 | MONDO:0100096 |
| asthma | 2 | MONDO:0004979 | MONDO:0004979 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 74.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 29 |
| PHASE1 | 18 |
| PHASE2 | 13 |
| PHASE4 | 8 |
| Not specified | 6 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07352566 | PHASE4 | NOT_YET_RECRUITING | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis |
| NCT04340076 | PHASE4 | COMPLETED | Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis |
| NCT04630652 | PHASE4 | COMPLETED | Risankizumab Long-term Remission Study |
| NCT04722640 | PHASE4 | UNKNOWN | Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity |
| NCT04908475 | PHASE4 | COMPLETED | Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy |
| NCT05969223 | PHASE4 | COMPLETED | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis |
| NCT06333860 | PHASE4 | COMPLETED | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) |
| NCT06346288 | PHASE4 | COMPLETED | A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease |
| NCT03398135 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis |
| NCT03671148 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) |
| NCT03675308 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy |
| NCT04524611 | PHASE3 | ACTIVE_NOT_RECRUITING | Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn’s Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn’s Disease (CD) |
| NCT04862286 | PHASE3 | ACTIVE_NOT_RECRUITING | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 |
| NCT05995353 | PHASE3 | RECRUITING | A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn’s Disease |
| NCT06100744 | PHASE3 | RECRUITING | A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab |
| NCT06624228 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis |
| NCT06641089 | PHASE3 | RECRUITING | Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response |
| NCT06880744 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab |
| NCT07071519 | PHASE3 | RECRUITING | A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis |
| NCT07177118 | PHASE3 | NOT_YET_RECRUITING | Risankizumab for Fibrostenotic Crohn’s Disease Treatment |
| NCT07499232 | PHASE3 | RECRUITING | A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn’s Disease |
| NCT02672852 | PHASE3 | COMPLETED | BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment |
| NCT02684357 | PHASE3 | COMPLETED | BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis |
| NCT02684370 | PHASE3 | COMPLETED | BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis |
| NCT02694523 | PHASE3 | COMPLETED | BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis |
| NCT03022045 | PHASE3 | COMPLETED | A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis |
| NCT03047395 | PHASE3 | COMPLETED | A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) |
| NCT03219437 | PHASE3 | COMPLETED | A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis |
| NCT03255382 | PHASE3 | COMPLETED | A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy |
| NCT03478787 | PHASE3 | COMPLETED | Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis |
| NCT03518047 | PHASE3 | COMPLETED | Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation |
| NCT03875482 | PHASE3 | COMPLETED | A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis |
| NCT03875508 | PHASE3 | COMPLETED | A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis |
| NCT04102007 | PHASE3 | COMPLETED | A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab |
| NCT04435600 | PHASE3 | COMPLETED | A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms |
| NCT04451720 | PHASE3 | COMPLETED | Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis |
| NCT04713592 | PHASE3 | COMPLETED | Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement |
| NCT06548542 | PHASE2 | RECRUITING | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn’s Disease |
| NCT06865105 | PHASE2 | RECRUITING | Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis |
| NCT07138898 | PHASE2 | NOT_YET_RECRUITING | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).